Report: Americans spent $71B on GLP-1 drugs in 2023
By 2023, semaglutide (Ozempic, Rybelsus and Wegovy) and tirzepatide (Mounjaro) products made up 70% of all U.S. GLP-1 spending.
Eli Lilly and Co.
Articles
Lilly promises to make weight-loss pill in United States in reshoring push
By making the expected blockbuster pill in the U.S., Lilly may be able to avoid the impact of Trump’s sweeping tariffs, including possible levies on pharmaceutical products.
Lilly stock soars after weight-loss pill’s trial results rival Ozempic’s shot
Trial data data showed Lilly’s experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.
Trump orders new efforts to lower drug prices
Trump’s order contains proposals to further lower the cost of insulin, importing more low-cost drugs and streamlining the federal approval process for some drugs.
Irish pharma exports to United States surge amid tariff threat
It was the second straight sizable increase, suggesting that U.S. drug makers with Irish manufacturing hubs like Indianapolis-based Eli Lilly and Co. could be stockpiling products ahead of any tariffs on the sector.
Pfizer ends development of potential pill obesity treatment
Pfizer had been hoping the once-daily pill treatment would give it an edge over leading weight-loss treatments like Zepbound from Eli Lilly and Co. and Novo Nordisk’s Wegovy, which are injectable.
Lilly sues Indianapolis clinic for selling split doses of popular weight-loss drugs
The drugmaker accuses Premier Weight Loss of risking patients’ health by selling altered, unsterile versions of its blockbuster drugs Mounjaro and Zepbound.
Skyrocketing cost of weight-loss drugs has state Medicaid programs looking for solution
At least 14 states already cover the cost of GLP-1 medications for obesity treatment for patients on Medicaid. Indiana is not one of them.
Trump administration nixes plan to cover anti-obesity drugs through Medicare
President Trump’s predecessor, Joe Biden, proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and Wegovy.
Purdue president: Universities must explore private alternatives to federal funding
Amid uncertainty around federal research funding, universities must explore private support, Purdue University President Mung Chiang told an tech industry group on Tuesday.
European regulators says Lilly Alzheimer’s drug shouldn’t get marketing approval
The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it.
Lilly adds online education, care services for Alzheimer’s to LillyDirect platform
The company said its goal is to reduce wait times for patients seeking access to specialists, creating more opportunities for early diagnosis and intervention.
Zepbound raises profile of Lilly’s direct-to-consumer sales initiative
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to connect directly with consumers on the platform since.
Novo Nordisk cuts Wegovy prices, following similar move for Zepbound by Eli Lilly
Novo Nordisk’s new offering follows a direct-to-consumer model that Eli Lilly launched last year.
Lilly cuts undisclosed number of jobs, ‘nothing large scale’
The reductions come at a time of significant growth overall for Lilly. and soon after the announcement of plans to build new manufacturing facilities at four yet-to-be-named U.S. locations.
LEAP spending nears $1B with projected budget shielded, investigation finds
The LEAP Research and Innovation District, led by the Indiana Economic Development Corp., is among the costliest economic development projects Indiana has attempted. But the agency’s structure obscures its spending and who benefits.
Weight-loss drugs aren’t just slimming waists. They’re shifting the economy.
Roughly 16 million people—that’s 6 percent of American adults—are taking GLP-1 weight-loss drugs, and that number is growing rapidly. Their collective purchasing power has the potential to profoundly reshape the economy.
Lebanon planning board OKs design for Lilly Medicine Foundry at LEAP District
The foundry will give the pharmaceutical maker the ability to research new ways of producing medicines.
Trump casts psychiatric and weight-loss drugs as threats to children
President Donald Trump has instructed his administration to scrutinize the “threat” to children posed by antidepressants, stimulants and other common psychiatric drugs.
Lebanon planning board to review designs for Lilly’s $4.5B foundry at LEAP District
IMAGE GALLERY: The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, scientists, operations personnel and lab technicians.